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ABSTRACT Fully differentiated pancreatic b cells
are essential for normal glucose homeostasis in mam-
mals. Dedifferentiation of these cells has been sug-
gested to occur in type 2 diabetes, impairing insulin
production. Since chronic fuel excess (“glucotoxicity”)
is implicated in this process, we sought here to identify
the potential roles in b-cell identity of the tumor sup-
pressor liver kinase B1 (LKB1/STK11) and the down-
stream fuel-sensitive kinase, AMP-activated protein
kinase (AMPK). Highly b-cell-restricted deletion of
each kinase in mice, using an Ins1-controlled Cre, was
therefore followed by physiological, morphometric,
and massive parallel sequencing analysis. Loss of LKB1
strikingly (2.0–12-fold, E<0.01) increased the expres-
sion of subsets of hepatic (Alb, Iyd, Elovl2) and neuronal
(Nptx2, Dlgap2, Cartpt, Pdyn) genes, enhancing glutamate
signaling. These changes were partially recapitulated
by the loss of AMPK, which also up-regulated b-cell
“disallowed” genes (Slc16a1, Ldha, Mgst1, Pdgfra) 1.8- to
3.4-fold (E<0.01). Correspondingly, targeted promoters
were enriched for neuronal (Zfp206; P51.3310233)
and hypoxia-regulated (HIF1; P52.5310216) transcrip-
tion factors. In summary, LKB1 and AMPK, through only
partly overlapping mechanisms, maintain b-cell identity
by suppressing alternate pathways leading to neuronal,
hepatic, and other characteristics. Selective targeting
of these enzymes may provide a new approach to
maintaining b-cell function in some forms of dia-
betes.—Kone, M., Pullen, T. J., Sun, G., Ibberson, M.,
Martinez-Sanchez, A., Sayers, S., Nguyen-Tu, M.-S.,
Kantor, C., Swisa, A., Dor, Y., Gorman, T., Ferrer, J.,
Thorens, B., Reimann, F., Gribble, F., McGinty, J. A.,
Chen, L., French, P. M., Birzele, F., Hildebrandt, T.,
Uphues, I., Rutter, G. A. LKB1 and AMPK differen-
tially regulate pancreatic b-cell identity. FASEB J.
28, 4972–4985 (2014). www.fasebj.org
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DIABETES MELLITUS IS a socioeconomically costly disease
affecting ;8% of the adult population worldwide (1).
The most prevalent form, type 2 diabetes (T2D),
involves a decline in the number of normally func-
tioning b cells through incompletely deﬁned mecha-
nisms (2).
Glucose-induced insulin secretion from the healthy
pancreatic b cell requires intracellular metabolism of
the sugar, increased intracellular ATP/ADP levels, and
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elevated free Ca2+ (3). Although T2D progression in
humans is characterized by a limited decrease in overall
b-cell mass (4, 5) it is increasingly apparent that a loss of
the normal differentiated state of the remaining cells,
and their consequent “glucose blindness,” also plays
a role (6–9). As well as decreased expression of signa-
ture genes, such as the glucose transporter Glut2/Slc2a2
and glucokinase (Gck) (6), b-cell dedifferentiation is
characterized by the increased expression of normally
repressed (“disallowed”) genes, such as LDHA and the
lactate transporter MCT-1/Slc16a1 (10), leading to ab-
errant fuel sensing (11).
Liver kinase B1 (LKB1), also called STK11, is a mam-
malian Ser/Thr kinase and tumor suppressor whose
invertebrate homologue (Par-4; ref. 12) controls em-
bryo polarity. LKB1 was shown [alongside calmodulin
kinase kinase 2 and transforming growth factor (TGF)-
b-activated kinase (TAK); ref. 13] to be one of 3 physi-
ologically relevant upstream kinases for AMP-activated
protein kinase (AMPK; refs. 14, 15), and othermembers
of the AMPK-related kinase (AMPKRK) family (16),
previously implicated in b-cell glucose sensing (17, 18).
Demonstrating the role of LKB1 in restricting cell
growth in humans, mutations in the human LKB1 gene
lead to Peutz-Jegers syndrome (19), an autosomal
dominant disorder characterized by the development of
intestinal polyps.
We (20, 21) and others (22) have previously demon-
strated that inactivation of either LKB1 or AMPK (23, 24)
selectively inpancreaticb cells anda smallnumberofother
cell types exerts dramatic effects on insulin secretion in
vivo. Thus, loss of LKB1 causes b-cell hyperplasia and an
increase in overall b-cell mass, associated with dramatic
changes in cell polarity. In marked contrast, deletion of
both AMPK catalytic subunits (a1, global; and a2, b
cells, brain) had no effect on b-cell size and mass but
strongly inhibited insulin secretion in vivo (23, 24). The
molecular underpinnings of these changes remain, how-
ever, unexplored.
To examine in detail the cell autonomous roles of
LKB1 and AMPK in the b cell, we have therefore de-
veloped new models using recombination based on Cre
expression under Ins1 promoter control, avoiding
deletion in the brain (25, 26). Metabolic analysis and
massive parallel sequencing of islets from each model
reveal both overlapping and distinct roles for LKB1 and
AMPK inb cells.We show that these enzymes are essential
to avoid the misexpression of a subset of genes normally
expressed at relatively low levels in b cells, including
those involved in glutamate signaling and in allowing
alternative metabolic fates for glucose.
MATERIALS AND METHODS
Generation of mutant mice lacking LKB1 selectively in
pancreatic b cells
Mice heterozygous for ﬂoxed alleles of the Lkb1/Stk11 gene
(mixed FVB/129S6 and C57BL/6 background; ref. 27) were
obtained from the Mouse Models of Human Cancer Con-
sortium [U.S. National Institutes of Health (NIH), Bethesda,
MD, USA; http://www.nih.gov/science/models/mouse/
resources/hcc.html] and backcrossed with C57BL/6 mice
4 times. Mice were then crossed withmice expressing Cre under
the mouse Ins1 promoter (Ins1.Cre), and the resulting
heterozygous mice were intercrossed with siblings to generate
Ins1LKB1-knockout (Ins1LKB1KO) mice (Lkb1ﬂ/ﬂ, Cre+).
Ins1LKB1KO mice were further bred with Lkb1ﬂ/ﬂ mice to
generate littermate controls (Lkb1ﬂ/ﬂ).
Generation of mutant mice selectively lacking AMPK a1 and
a2 in pancreatic b cells
Mice homozygous for Ampka1ﬂ/ﬂ (Dr. Benoit Viollet, Institut
National de la Sante´ et de la Recherche Me´dicale, U1016, Paris,
France) were crossed to mice heterozygous for ﬂoxed alleles of
AMPKa2 (Ampka2ﬂ/+; ref. 23). The resulting double hetero-
zygotes (Ampka1ﬂ/+,a2ﬂ/+) were crossedwith Ins1Cre-expressing
animals to generate triple heterozygous mice (Ampka1ﬂ/+, a2ﬂ/+,
Cre+). The latter were then bred with mice homozygous for both
ﬂoxed Ampka1 and a2 alleles (Ampka1ﬂ/ﬂ, a2ﬂ/ﬂ) to produce
Ins1AMPKdouble-KO(Ins1AMPKdKO)mice (Ampka1ﬂ/ﬂ,a2ﬂ/ﬂ,
Cre+). Ins1AMPKdKOmice were further crossed with Ampka1ﬂ/ﬂ,
a2ﬂ/ﬂmice to generate littermate controls (Ampka1ﬂ/ﬂ,a2ﬂ/ﬂ). All
mice were maintained on a C57BL/6 background.
Mouse maintenance and diet
Animals were housed 2 to 5 per individually ventilated cage in
a pathogen-free facility with 12-h light-dark cycle and had free
access to standard mouse chow diet. All in vivo procedures de-
scribed were performed at the Imperial College Central Bio-
medical Service and approved by the UK Home Ofﬁce Animals
Scientiﬁc Procedures Act, 1986 (HO License PPL 70/7349).
Isolation of mouse islets and b cells
Islets were isolated by pancreatic distension and digestion with
collagenase as described previously (28). b Cells were puriﬁed by
ﬂuorescence-activatedcell sorting(FACS)asdescribedpreviously
(29) and directly collected in Trizol (Life Techonologies, Grand
Island, NY, USA).
RNA extraction and massive parallel RNA
sequencing (RNAseq)
Islets (50–100) extracted from Ins1LKB1KO or Ins1AMPKdKO
mice and their wild-type (WT) controls, age 12–14 wk, were in-
cubated in RPMI medium containing 11 mM glucose, 10% FCS,
100 IU/ml penicillin, and 100 mg/ml streptomycin, at 5% CO2
and 37°C for 24 h prior to being lyzed in RNA lysis buffer using
the RNAeasy kit according to the manufacturer’s instructions
(Qiagen, Valencia, CA, USA).
Library preparation and sequencing
All libraries were prepared using the TruSeq RNA Sample
Preparation Kit v2 (Illumina, San Diego, CA, USA) according
to the manufacturer’s instructions. In brief, magnetic beads
containing polydT molecules were ﬁrst used to purify mRNA
from 250 ng of total RNA. Second, samples were chemically
fragmented and reverse transcribed into cDNA. Finally,
end repair and A-base tailing was performed before
Illumina adapters were ligated to the cDNA fragments. Puriﬁed
samples were ampliﬁed by 15-cycle PCR. Ampliﬁed material was
validated and quantiﬁed using an Agilent 2100 bioanalyzer
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and the DNA 1000 Nano Chip Kit (Agilent, Technologies,
Santa Clara, CA, USA).
Libraries were loaded onto the channels of the ﬂowcell at
9 pM concentration. Sequencing was carried out on the Hiseq
2000 (Illumina) by using Illumina’s Trueseq Single Read
Cluster Generation Kit v3 CBot Hs and running 50 cycles with
the Cycle Sequencing Kit according to the manufacturer’s
instructions.
Transcriptomic data analysis and identiﬁcation of putative
transcription factor binding sites
Datasets from RIPCre strains had reads mapped to the mouse
genome (Ensembl56) using the Genomatix Mapping station al-
gorithm(allowing for up to 3mismatches, no indels; Genomatix,
Munich, Germany). Reads were additionally mapped to a set of
(artiﬁcial) splice junctions of all known exons in the mouse
preserving exon order within a gene. Reads from Ins1Cre strains
were mapped to the mouse genome (Ensembl66) using the
Bowtie2-Tophat2 spliced read mapper (30). Differential ex-
pression was analyzed using SageBetaBin (31), and expression
values [reads per kilobase of transcript per million reads read
(RPKM)] were calculated according to Mortazavi et al. (32).
Transcription factor binding sites (TFBSs) enriched in the pro-
moters ofdifferentially expressedgeneswere identiﬁedusing the
Whole Genome rVista tool (33).
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
analysis (Kanehisa Laboratories, Kyoto, Japan; http://www.
genome.jp/kegg/) was performed using the Database for Anno-
tation,Visualizationand IntegratedDiscovery (DAVID) functional
analysis tool (U.S. National Institute for Allergy and Infectious
Diseases,NIH,Bethesda,MD,USA;http://david.abcc.ncifcrf.gov).
Expression patterns in mouse tissues and the likely functions of
identiﬁed genes were assessed by reference to BioGPS (Scripps
Research Institute, La Jolla, CA, USA; http://biogps.org/).
Gene set enrichment analysis (GSEA)
GSEA(34)wasperformedbyﬁrst rankingdifferentially expressed
genes according to fold change (high to low; either absolute or
taking direction into account) and testing for enrichment against
MSigDB V4 gene sets, or a gene set containing disallowed genes.
Empirical P values were calculated by performing a bootstrap
where gene labels were shufﬂed10,000 times and theenrichment
was recalculated.Anestimateof the falsediscovery rate (FDR)was
calculated using the Benjamini-Hochberg procedure using the
Bioconductor multtest package in R (35). An FDR of 30% was
considered as indicating signiﬁcant enrichment.
RNA-Seq accession codes
Raw sequence data for RNA-Seq are available at the European
Molecular Biology Laboratory–European Bioinformatics In-
stitute (EMBL-EBI) ArrayExpress website (accession number
E-MTAB-2791; https://www.ebi.ac.uk/arrayexpress/).
Imaging of pancreatic slices and optical projection
tomography (OPT)
Permeabilized slices were prepared as described previously
(20) and blotted with primary antibodies, anti-guinea pig
insulin (1:200; Dako, Ely, UK), anti-rabbit glucagon (GCG;
1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA), and
anti-rabbit NPTX2 (5 mg/ml; Abcam, Cambridge, UK). Slices
were visualized with Alexa Fluor 488 goat anti-guinea pig IgG
and with Alexa Fluor 568 donkey anti-rabbit IgG (Invitrogen,
Paisley, UK) using an Axiovert 200 M microscope (Zeiss,
WelwynGardenCity, UK). ImageJ software (Wayne Rasband,
NIH, Bethesda, MD, USA) was used to calculate b- and a-cell
mass. OPT of whole pancreata stained with anti-insulin
antibodies was performed as described previously (20).
Islet isolation for calcium imaging
Pancreatic islets were isolated as described above, dispersed
into single b cells, and plated on glass coverslips (36). Imaging
experiments were performed essentially as described pre-
viously (37) on an Olympus IX-71 microscope with 340 objec-
tive, using an Andor CMOS Zyla camera (Andor Technology,
Belfast, UK) and MT-20 excitation system equipped with
a Hg/Xe arc lamp controlled by Micro-Manager software
(38). Images were acquired at a frequency of 0.5 Hz with
typical excitation times of 50 ms.
Statistical analysis
Data are presented as means 6 SEM. Signiﬁcance was assessed
by Student’s t test with appropriate Bonferroni correction, or
ANOVA using Prism (GraphPad, San Diego, CA, USA).
RESULTS
Effect on glucose homeostasis and insulin secretion of
deleting LKB1 or AMPK highly selectively in the b cell
with Ins1Cre
To avoid the complications associated with deletion of
LKB1 (39) or AMPK (23, 24) in the brain after Ins2Cre-
mediated recombination (40) we used a knock-in
mouse in which Cre recombinase was introduced at the
Ins1 locus (refs. 25, 26 and unpublished results). In
contrast to RIP2LKB1KO mice, postnatal body weight
gain was normal in Ins1LKB1KO animals; for males
aged 10–14 wk: WT, 26.9 6 0.4 g (n54 mice), and for
Ins1LKB1KO, 27.4 6 0.9 g (n58, P.0.05). Further-
more, Ins1LKB1KO animals showed no signs of paral-
ysis or premature mortality up to 12 mo of age (results
not shown).
Examined at ages up to 12 wk, Ins1LKB1KO mice
displayed improved glucose tolerance (Fig. 1A), un-
altered insulin sensitivity (Fig. 1B), and sharply im-
proved in vivo insulin secretion (Fig. 1C) compared to
WT littermates. An increase in b-cell size (Fig. 2A–J),
and the appearance of “rosette-like” arrangements of
b cells around a central organizing center (Fig. 2G,
H), were also observed, as described previously after
RIP2Cre-mediated (20) or Pdx1CreER-mediated
(21) LKB1 deletion. Pancreatic b-cell mass was also
signiﬁcantly increased (Fig. 2K, L, P) as well as b-cell size
(Fig. 2M, N) and b:a cell ratio, consistent with earlier
ﬁndings using alternative Cres (20, 21). Examined in vitro,
glucose-stimulated insulin secretion from Ins1LKB1KO
islets was largely unchangedwith respect to controlmouse
islets (Supplemental Fig. S1A and Fig. 6C).
We next generated an analogous mouse line in which
AMPK activity was eliminated selectively in the b cell by
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deleting both catalytic subunits of AMPK (a1 and a2).
Body weight gain was not different in Ins1AMPKdKO
(Cre+, a1f/f, a2f/f) mice with respect to Cre2 controls (at
10 wk, means6SEM,: WT, 27.0760.42 g; AMPKdKO,
27.7560.20 g).
Ins1AMPKdKO mice displayed a more minor pheno-
type compared to that observed in the RIP2AMPKdKO
model (23, 24). Thus, glucose tolerance was only
slightly impaired in Ins1AMPKdKO animals (Fig. 1D),
with blood glucose signiﬁcantly elevated only at 30 min
during intraperitoneal glucose tests (IPGTTs). More-
over, whereas insulin sensitivity was markedly im-
proved in RIP2AMPKdKO mice vs. heterozygous
controls (23), no alterations in this parameter were
seen in Ins1AMPKdKO animals (Fig. 1E). Finally,
whereas the ﬁrst phase of glucose-stimulated in-
sulin release in vivo was completely abolished in
RIP2AMPKdKO mice (23), release of the hormone
was diminished by only ;50% in Ins1AMPKdKO mice
vs. controls (Fig. 1F). No evident changes in b-cell
mass were observed in Ins1AMPKdKO mice vs. litter-
mate controls (pancreatic b-cell area: 0.3160.06 vs.
0.3960.5%, respectively, n55–6 mice/genotype),
though the ratio of b:a cells was signiﬁcantly re-
duced in these mice (Fig. 3). In common with
RIP2AMPKdKO mice (23), a dramatic improvement
in glucose-stimulated insulin secretion was observed
in vitro with islets isolated from Ins1AMPKdKO mice
(Supplemental Fig. S1B).
Deep sequencing identiﬁes gene modules
differentially affected in Ins1LKB1KO and
Ins1AMPKdKO mouse islets
We next explored whether the phenotypic differences
between Ins1LKB1KO and Ins1AMPKdKO mouse b cells
might be reﬂected at the transcriptome level using RNA-
Seq (Supplemental Tables S1 and S2).
Ins1LKB1KO mouse islets displayed no signiﬁcant
changes in b-cell markers, including Slc2a2 (Glut2),
Pdx1, MafA, NeuroD, and Nkx6.2, while Pcsk1 mRNA
was up-regulated 1.75-fold, consistent with an in-
crease in b-cell volume within the islet. Conversely,
expression of the a-cell-enriched factor Arx (41) was
signiﬁcantly (0.65-fold, E50.05) lowered, and Gcg
mRNA levels tended (0.84-fold, E50.19) also to be
decreased, consistent with the increase in b:a cell
ratio (Fig. 2O). Somatostatin (Sst) mRNA levels also
showed a minor tendency to decrease (0.74-fold,
P50.31) in Ins1LKB1KO islets. Signiﬁcant increases
were also observed in the expression of genes usually
restricted to a cells (42) including Pcsk2 [encoding
prohormone convertase 2 (PC2), 1.61-fold, E,0.01]
as well asDpp4 (1.51-fold, E50.03). The latter ﬁndings
may suggest that LKB1 ablation loosens the re-
pression in the b cell of a subset of usually a-cell-
restricted genes.
Conversely, in Ins1AMPKdKO mouse islets, Slc2a2
(Glut2; 0.59-fold, E50.04; ref. 43), mRNA levels were
Figure 1. Glucose homeostasis and insulin secretion in Ins1LKB1KO and Ins1AMPKdKO mice. A–C) Glucose (1 g/kg
intraperitoneal) tolerance (A), insulin (0.75 U/kg) tolerance (B), and glucose (3 g/kg)-induced insulin secretion (C) in WT or
Ins1LKB1KO mice (10- to 12-wk-old males, n53 WT, 5 KO). D–F) As in A–C but comparing WT (AMPKa1f/f:AMPKa2f/f) and
Ins1AMPKdKO mice (n55–10 mice/genotype). *P , 0.05, **P , 0.01 for effects of genotype.
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signiﬁcantly reduced compared to WT controls, and
other b-cell markers, including Ins2 and Slc30a8, also
tended to be more weakly expressed in the absence of
AMPK. On the other hand, Gcg and Arx mRNA levels
tended to increase, while Pcsk2 was signiﬁcantly up-
regulated (1.21-fold, E,0.04). Thus, AMPK signaling
is required to maintain normal islet b-cell mass and is
not rescued by other AMPK-related kinases.
To identify gene clusters affected by either kinase, we
ﬁrst used GSEA (ref. 33; see Materials and Methods and
Supplemental Tables S3 and S4). Whereas genes in-
volved in neuronal function (synapse organization,
synaptic transmission, synaptogenesis, etc.) were strongly
and signiﬁcantly enriched in Ins1LKB1KO islets (Fig.
4A, Table 1, and Supplemental Fig. S2A), the most
strongly enriched gene groups in Ins1AMPKdKO islets
were involved in second messenger signaling and
metal ion transport (Supplemental Table S3). None-
theless, a tendency was observed for enrichment of neuro-
nal genes in Ins1AMPKdKOislets, though thisdidnot reach
statistical signiﬁcance (Fig. 4B and Supplemental Fig. S2B).
Wenext compared genes whichwere changed in both
or in a single Ins1Cre-deleted model (Supplemental
Tables S5–S7) and identiﬁed functional pathways using
KEGG analysis (see Materials and Methods). Pathways
in cancer was the top hit for genes regulated speciﬁcally
in the Ins1LKB1KO model, with MAPK signaling path-
way, apoptosis, and pancreatic cancer clusters all having
FDR ,30%. These changes are thus consistent with in-
creasedoverallb-cellmassobserved in Ins1LKB1KObutnot
Figure 2. LKB1 deletion increases b-cell
size and mass in Ins1LKB1KO mice.
A–J) Consecutive pancreatic sections
from WT (A–I) or Ins1LKB1KO (B–J)
mice were stained for DAPI (A, B), E-
cadherin (C, D), insulin (E, F), insulin
plus E-cadhrin (G, H), or insulin plus
GCG (I, J). Scale bars 5 20 mm. K, L)
Representative optical tomography pro-
jections for whole pancreata from WT
(K) and Ins1LKB1KO (L) mice. Scale
bar 5 400 mm. M, N) Distribution of
b-cell sizes (M) and average b-cell size
(N) was calculated from data as shown
in C and D. O) Quantitation of the data
in I and J. P) Quantiﬁcation of OPT
data from K and L. n 5 3–6 mice/
genotype. *P , 0.05; Student’s t test.
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observed Ins1AMPKdKO mouse islets (Supplemental
Table S8).
In contrast, the gene clusters speciﬁcally enriched in
Ins1AMPKdKO were topped by ribosome, with protea-
some, spliceosome, and DNA replication among the top
hits. This is consistent with the role of AMPK in inhibiting
protein production through decreased ribosome bio-
genesis and protein translation, and also inhibiting pro-
teosomal degradation of proteins in low cellular energy
states (Supplemental Table S9).
Finally, we examined gene groups whose changes were
common to both Ins1LKB1KO and Ins1AMPKdKO islets
(Supplemental Table S10). Notable among pathways up-
regulated in both models were a number of cancer and
proliferation pathways, including cell cycle, melanoma,
glioma, bladder cancer, and colorectal cancer. Axon
guidance was also signiﬁcantly enriched, suggesting that
a subset of the LKB1-dependent cancer-related and
neuronal genes are likely to be regulated via AMPK.
Comparison between the effects of LKB1 vs. AMPK
deletion across Cre models
We reasoned that comparisons of the islet transcriptome
in additional b-cell-selective LKB1KO and AMPKKO
models might validate targets for each kinase iden-
tiﬁed above in the Ins1Cre-deleted models and pro-
vide further evidence for b-cell-autonomous actions
of each kinase. We therefore performed deep se-
quencing on islets from mice inactivated for either
LKB1 (20) or AMPK (23) using the RIP2Cre trans-
gene, as described previously (Supplemental Tables
S11 and S12). In addition, microarray analysis was
performed on islets from Pdx1CreERLKB1KO mice
(ref. 21 and Supplemental Table S13). In the latter
model, LKB1 deletion was achieved acutely in the
adult mouse b cell by tamoxifen-mediated activation
of Cre (21).
We next ranked the changes in mRNAs levels in
Ins1LKB1KO vs. control islets. Genes were further ﬁl-
tered as displaying a signiﬁcant (E,0.1 or P,0.05)
and$1.4-fold change in at least one further LKB1-null
strain (RIP2Cre or Pdx1CreER). We note that this
conservative approach may conceivably exclude gen-
uine b-cell targets, should these be further modiﬁed
as a result of undeﬁned brain-derived signals, but is
likely to be relatively less prone to identifying false
positives (i.e., a type I statistical error). A comparison
of the changes observed was then made for each gene
in the 2 AMPKdKO models. The resulting analysis is
shown in Fig. 5 and Supplemental Fig. S3. A clear
conservation of differentially expressed genes was
apparent when considering as groups the 3 LKB1-null
and the 2 AMPK-null models, irrespective of the Cre
used (Supplemental Fig. S3). More divergence was
seen between the models deleted for either kinase,
as anticipated. Thus, all 12 of the most induced genes
in Ins1LKB1KO mouse islets were also up-regulated
in RIP2LKB1KO and Pdx1CreERLKB1KO islets
(Fig. 5). Of these, 8/12 and 7/12, respectively, were
also increased in Ins1AMPKdKO and RIP2AMPKdKO
mice (Fig. 5). Moreover, 4/12 (Nptx2, Astn1, Kcnq2,
and Mt3) were signiﬁcantly up-regulated in all 5 KO
models, suggesting that they represent biologically
relevant targets for LKB1-AMPK signaling in the
b cell.
Strikingly, 49% (27/55) of the most up-regulated
genes in Ins1LKB1KO islets, and one other LKB1-null
strain, were usually expressed exclusively or princi-
pally in neuronal tissues (as identiﬁed using BioGPS);
this proportion rose to 56% for the 25 most highly
induced genes. A further 9.1% (5/55) were genes
enriched in the liver or small intestine. These pro-
portions were 40 and 11%, respectively, for the top 45
differentially expressed genes. Of the top 12 most
strongly induced genes in Ins1LKB1KO mouse islets,
10 fell into one of these 2 groups (Fig. 5). The degree
of overlap between different models is shown in Sup-
plemental Figs. S6–S8.
Divergence was less marked for down-regulated
genes, with the expression of all 11 of the most-
repressed genes in Ins1LKB1KO islets also being sim-
ilarly inhibited in the 4 other KO models, albeit with
differences in rank order (Fig. 5). A number (8/30,
26.6%) of neuronally enriched genes were also
present in the repressed group. Interestingly, 2 of
the 4 most repressed genes across all 5 KOs, Slc12a7,
encoding a K/Cl2 symporter, and Mcoln3 (also
Figure 3. Deletion of AMPK catalytic subunits with Ins1Cre
alters islet b:a cell ratio. Pancreata from Ins1AMPKdKO mice
and controls were ﬁxed, sectioned, and subjected to immu-
nocytochemical analysis for insulin and GCG as given in
Materials and Methods. n 5 3 mice/genotype in each case.
*P , 0.05; paired Student’s t test.
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called Trpm3), are usually very weakly expressed in neu-
ronal tissues, but strongly expressed in other tissues.
Glutamate signaling and addiction-related genes
More detailed inspection identiﬁed important func-
tional clusters among the neuronally enriched genes
(Fig. 5; Supplemental Fig. S3). First, a subset was
identiﬁed that was involved in glutamate signaling
(Nptx2, Gria3, Dlgap2), while 2 genes (Cartpt and Pdyn)
are usually associated with addictive behavior. Up-
regulation of the former group was apparent in all 3
LKB1KO models, while Gria1, encoding the ionotropic
glutamate receptor GluR1 (44), was also up-regulated in
Ins1LKB1KO islets. Nptx2 and Dlgap2 expression was
also signiﬁcantly increased in Ins1AMPKdKO islets
(Supplemental Table S2). Dlgap2 encodes discs, large
(Drosophila) homologue-associated protein 2 (45),
a membrane-associated protein that forms part of the
postsynaptic density scaffold and interacts with post-
synaptic density 95 (PSD95). The latter, in turn,
binds to N-methyl-D-aspartate (NMDA) receptors and
Shaker-type K+ channels. Interestingly,Kcna2, a Shaker
channel, was also strongly up-regulated by LKB1 or
AMPK deletion (Fig. 5). Immunocytochemistry con-
ﬁrmed the induction of NPTX2 at the protein level in
Ins1LKB1KO b cells (Fig. 6A).
Consistent with increased glutaminergic signaling
in Ins1LKB1KO b cells, kainate, which binds to and
activates ionotropic glutamate receptors (44), caused a
more pronounced rise in cytosolic-free Ca2+ ([Ca2+]cyt)
in islets from Ins1LKB1KO than control mice (Fig. 6B).
Furthermore, at low (3 mM) glucose, kainite stimulated
insulin secretion from Ins1LKB1KO but not control
islets (Fig. 6C).
Disallowed genes
We (9, 10) and others (46) have previously described
a list of .60 housekeeping genes that are expressed
in the majority of mammalian tissues at quite high
Figure 4. GSEA for neuronal genes in Ins1LKB1KO (A) or Ins1AMPKdKO (B) mice. A) GSEA was performed against MSigDB
(V4) biological process gene ontolology categories (C5, BP) revealing signiﬁcant enrichment for neuronal genes for
Ins1LKB1KO [MSigDB category: NERVOUS_SYSTEM_DEVELOPMENT; Enrichment (ES) score50.41 FDR50.06]. In Ins1-
AMPKdKO, this category was not signiﬁcantly enriched (ES score50.02; FDR51; right panel). Data are expressed as absolute fold
change irrespective of the direction of change. Blue line plot shows the cumulative ES score for this functional gene category.
Vertical bars indicate the positions of the neuronal genes in the ranked differential expression lists. Line plot at the bottom shows
the log2-fold changes of the genes in the ranked lists. Because the initial gene lists were ranked by absolute fold change, both up-
and down-regulated genes are found at the top of the lists.
TABLE 1. Ins1LKB1KO and Ins1AMPKdKO: synapse cluster
Category Term Count % P List total FDR
GOTERM_CC_FAT GO:0045202;synapse 18 4.37 9.67E-04 284 1.24
GOTERM_CC_FAT GO:0044456;synapse part 14 3.40 0.00107 284 1.38
GOTERM_CC_FAT GO:0008021;synaptic vesicle 7 1.70 0.00430 284 5.45
GOTERM_CC_FAT GO:0030135;coated vesicle 8 1.94 0.0225 284 25.67
GOTERM_CC_FAT GO:0030136;clathrin-coated vesicle 7 1.70 0.0306 284 33.25
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levels, but at much lower levels in islets and b cells; of
these, 11 genes were reported in both of the previous
studies (10). We noticed that several of the genes in
both lists were up-regulated in RIP2AMPKdKO and
Ins1AMPKdKO islets. GSEA analysis (Fig. 7A) revealed
that 16 members of this family were speciﬁcally up-
regulated in Ins1AMPKdKO islet models. By contrast,
Ins1CreLKB1KO islets showed a negative enrichment
for this class (Fig. 7A).
The most up-regulated genes in this group are com-
pared in the Ins1AMPKdKOandRIP2AMPKdKOmodels
in Fig. 7B. Suggesting that these increases are unlikely to
reﬂect an enrichment of AMPKdKO islets with nonislet
material, levels of the pancreatic acinar cell marker am-
ylase were not different between Ins1- or RIP2AMPKdKO
vs. control islets. Moreover, examined in FACS-sorted
mouse islet cells (47), with the exception of Oat and
Igfbp4, similar levels of expression of each gene were
detected in WT b and a cells (Supplemental Table 14).
Finally, and providing direct conﬁrmation of the above
conclusion, expression of both Ldha and Acot7 were sig-
niﬁcantly increased in FACS-puriﬁed b cells from
Ins1AMPKdKO vs. control mice (Fig. 7C).
Hepatic genes
Striking changes were observed across all 3 LKB1KO plus
Ins1AMPKdKO models in the expression of 3 genes
largely restricted to the liver, namely, albumin (Alb),
iodotyrosine deiodinase (Iyd), and elongation of very long
chain fatty acids 2 (Elovl2). Furthermore, the liver/kidney-
enriched gluconeogenic gene, fructose 1,6-bisphoshatase-
1 (Fbp1), was signiﬁcantly up-regulated in 2 of the 3
LKB1KO models (RIP2- and Pdx1CreER), and tended
(P50.12) to be activated in Ins1LKB1KO mouse islets.
Fructose 1,6-biosphosphatase-2 (Fbp2), usually restricted
to stomach, small intestine, and skeletal muscle, was sig-
niﬁcantly up-regulated in each of the LKB1models and in
RIP2AMPKdKO mice (Fig. 5), suggesting increased po-
tential for gluconeogenesis.
Figure 5. Differentially regulated genes after
LKB1 or AMPK deletion in b cells. Heat map
showing genes signiﬁcantly up-regulated (red
hues) or down-regulated (blue hues) by .1.4-
fold in islets after deletion of the indicated
kinases. Gray indicates genes absent from 1 or
more samples (see Supplemental Tables S1 and
S2). All genes shown were up-regulated in
Ins1CreLKB1KO vs. control islets and $1 other
LKB1KO model. Color bars at left indicate
neuronal genes (brown) and liver-enriched
genes (purple). Arrows indicate messages selec-
tively enriched in LKB1 vs. AMPKdKO models.
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G-protein-coupled receptors
Purinergic receptor P2Y, G-protein coupled, 14 (P2ry14)
expression was the most strongly (;16-fold) up-regulated
gene in Ins1LKB1KOandRIP2LKB1KO islets andwas also
induced in Pdx1CreERLKB1KO and both AMPKdKO
models (Fig. 5).
Interestingly, GCG receptor (Gcgr) expression was
substantially (;2-fold) reduced after LKB1 deletion in
all 3 models, and even more markedly (;4-fold) re-
duced in Ins1AMPKdKO islets, with also a strong ten-
dency (P50.064) toward a reduction in RIP2AMPKdKO
islets. Thus, Gcgr seems likely to be a direct target for
the actions of AMPK. Similarly, glucose-dependent
insulinotropic polypeptide (GIP) receptor (Gipr) and
GCG-like peptide-1 (GLP-1) receptor (Glpr) expression
were both signiﬁcantly (;50%; P,0.002, 0.007, re-
spectively) down-regulated in Ins1AMPKdKO islets.
T2D-associated genes
Genome-wide association studies (GWASs) have now
identiﬁed .70 loci associated with T2D (48). Of the
genes closest to the implicated single-nucleotide poly-
morphisms (SNPs), we identiﬁed relatively few whose
expression was affected in any of the LKB1KO or
AMPKKOmodels. However, the GWAS gene transducin-
like enhancer of split 1 (Tle1), encoding an RNA
pol II interactor involved inWnt andNotch signaling, as
well as histone deacetylase recruitment (49), was sig-
niﬁcantly up-regulated in all 3 LKB1KO models exam-
ined and in Ins1AMPKdKO islets. Furthermore, ex-
pression of Dock4, encoding the guanine nucleotide
exchange factor for Rac, and another binding partner
ofb-catenin and regulator ofWnt signaling (50), was up-
regulated in all LKB1KOmodels and in Ins1AMPKdKO
islets (Fig. 5). These observations support earlier ﬁnd-
ings (51) indicating that LKB1, at least partly via AMPK
activation, suppresses canonical Wnt signaling in mam-
malian cells.
T2D-regulated genes
We next asked whether a decrease in LKB1 or AMPK ac-
tivity in the islet might lead to changes that mimic those
observed in T2D (52). Implicating a role for impaired
AMPK activation in the disease, theb-cell-disallowed genes
Ldha, Slc16a1, Acot7, Mgst1, and Pdgfra are all increased
T2D islets (52). On the other hand, Nptx2, Dlgap2, and
Cartpt are not reported to change.
Common promoter regions in the regulated genes
We wondered whether the LKB1/AMPK-regulated genes
may be the target for a common set of transcription
Figure 6. Up-regulation of neuronal genes in Ins1LKB1KO mice is associated with enhanced glutamate signaling. A)
Immuncytochemical analysis of pancreatic slices from the indicated mouse strains stained for NPTX2. Scale bar 5 50 mm. B)
Glutamate receptor signaling to increases in intracellular [Ca2+]cyt in control (gray trace; n518) and Ins1LKB1KO (black; n516)
separate b cells, from 6 independent experiments. Mean amplitude of [Ca2+] peak and AUC in response to kainite were gathered
from 7 WT and 6 Ins1LKB1KO mice. **P , 0.01. C) Insulin secretion in response to kainate and high glucose in islets from
control and Ins1LKB1KO mice (n54 animals/genotype). Incubations were performed in triplicate and involved 6 islets/tube.
*P , 0.05, **P , 0.01, ****P , 0.0001.
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factors. To this end, we searched for conserved TFBSs
overrepresented in the upstream regions of differen-
tially expressed genes, as described in Materials and
Methods. This revealed sites common to a range of fac-
tors, as shown in Table 2. Strikingly, the most enriched
TFBS upstream of genes differentially expressed in
both Ins1LKB1KO and Ins1AMPKdKO was Zfp206
(Znf206/Zscan10) (P51.3310233). Increased expres-
sion of this gene is associated with neuronal differen-
tiation (53), and several of the most up-regulated
neuronal genes (e.g., Nptx2 and Dlgap2) have putative
Zfp206 binding sites. Zfp206 is more signiﬁcantly
Figure 7. GSEA for disallowed genes in
Ins1LKB1KO and Ins1AMPKdKO mouse islets.
A) Analyses were performed as described in
Materials and Methods and in the legend to Fig.
4. Disallowed genes were selected as described
previously (9, 10, 46). Here the differentially
expressed genes were ranked by fold change
(high to low) and tested for enrichment against
the set of disallowed genes. Genes with in-
creased expression are indicated in green,
decreased expression in red. Plot at bottom
indicates log2-fold changes of the genes.
Ins1AMPKdKO and RIP2AMPKdKO show en-
richment for disallowed genes among the genes
that are up-regulated (left panel). In contrast,
the situation with LKB1 is less clear, with
Ins1LKB1KO showing enrichment for disal-
lowed genes among the down-regulated genes
(top right), and RIP2LKB1KO showing no
clear enrichment for disallowed genes (bottom
right). Red bracket indicates signiﬁcantly
enriched genes. B) Comparison of up-regulated
disallowed genes in Ins1AMPKdKO and
RIP2AMPKdKO mice. Heat maps show the
ranking of disallowed gene changes. C) Acot7
and Ldha expression is up-regulated in b cells
lacking AMPKa1/a2. Expression of Ins2, Acot7,
and Ldha was measured by qRT-PCR in b cells
sorted from islets corresponding to control and
Ins1AMPKdKO mice (n53 animals/genotype).




CTCTGGCACAAGCT-39 and Ldha, 59-ATGAA-
GGACTTGGCGGATGA-39 and 59-ATCTCG-
CCCTTGAGTTTGTCTT-39.Values were normal-
ized to Ppia and expressed in relative quantities
related to a control mouse. Data are shown as
means 6 SEM. *P , 0.05.
TABLE 2. Top 10 transcription factor binding sites enriched upstream of genes differentially expressed
in Ins1LKB1KO and Ins1AMPKdKO
Rank Name Hits in submitted regions Hits on genome 2log10 (P)
1 Zfp206 1997 23,846 32.8816
2 E2F-4 2040 25,565 23.3829
3 SP1:SP3 2445 31,775 20.0247
4 Egr-1 2649 35,444 15.8367
5 HIF1 612 6,863 15.6096
6 SAP-1a 1322 16,794 13.8834
7 SP2 1380 17,684 13.3895
8 GABPalpha 2155 28,850 12.9993
9 GABP 2693 36,795 12.4291
10 SP4 1415 18,330 12.4105
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enriched in genes only differentially expressed in
the Ins1LKB1KO model (P59.1310296), consistent
with the more signiﬁcant degree of up-regulation
of neuronal genes observed in this model vs.
Ins1AMPKdKO (Fig. 4 and Supplemental Figs. S3
and S4).
Hypoxia-inducible factor 1 (HIF1) binding sites
were also enriched in genes differentially expressed in
both models (P52.5310216). More detailed exami-
nation, taking the direction of differential expres-
sion into account, revealed that HIF1 sites were
enriched in genes signiﬁcantly up-regulated in just
the Ins1AMPKdKOmodel (P55.7310213) and also in
genes down-regulated in just the Ins1LKB1KO model
(P52.2310226). LKB1 and AMPK therefore both
appear to have nonoverlapping roles in HIF1 regula-
tion. Hypoxia is known to up-regulate a number of
b-cell disallowed genes (e.g., Ldha and Slc16a1; ref.
54), and the enrichment of HIF1 binding sites in genes
selectively up-regulated in Ins1AMPKdKO supports
a role for this transcription factor in disallowed gene
suppression.
DISCUSSION
The present study provides the ﬁrst detailed tran-
scriptomic analysis exploring the roles of LKB1 and
AMPK in the endocrine pancreas. First, we conﬁrm
several previous ﬁndings (20–23) based on the de-
letion of these kinases in multiple tissues, showing
that when restricted to the b cell, loss of LKB1 exerts
markedly different effects on insulin secretion and
glucose metabolism compared to the loss of AMPK
(Figs. 1–3). We now demonstrate that these func-
tional differences are mirrored by complex alter-
ations at the level of gene expression (Figs. 4 and 5,
Supplemental Figs. S1–S3, and Supplemental Tables
S1–S13).
Differences in gene expression between Ins1LKB1KO
and Ins1AMPKdKO islets are likely to reﬂect signal-
ing by members of the AMPKRK family (16) in the
former case. However, the identity of the kinases in-
volved is unclear. Thus, deletion of synapses of
amphids defective kinase-A (SAD-A) in the pancreas
causes defective glucose signaling and the appearance
of small islets (55), suggesting that this enzyme rather
opposes the actions of LKB1, mediating instead
the effects of mammalian target of rapamycin-1
(mTORC1). Likewise, deletion of salt-inducible kinase
2 (SIK2; ref. 56) impairs glucose tolerance and insulin
secretion.
An interesting observation, replicating ﬁndings
in RIP2AMPKdKO islets (23), is that while glucose-
stimulated insulin secretion was strongly impaired
in vivo in Ins1AMPKdKO mice (Fig. 1C), it was
enhanced from isolated islets (Supplemental Fig.
2B). There may be several explanations for this
difference. First, it may reﬂect the loss in vitro of
an action of circulating factors that normally regu-
late insulin secretion in vivo. Obvious candi-
dates are the incretins GIP and GLP-1, as well as
GCG, given the lowered expression of the corre-
sponding receptors in Ins1AMPKdKO mice. In ad-
dition, we noted a signiﬁcant (P,0.01) ;2-fold
up-regulation in the expression of both the somato-
statin receptor gene Sstr1, and the adrenoreceptor
Adrb1 in Ins1AMPKdKO islets, expected to potenti-
ate the inhibitory actions of the cognate hormones
on insulin secretion; neither gene was affected in
Ins1LKB1KO islets.
Identiﬁcation of genes differentially regulated by
LKB1 and AMPK
It seems reasonable to speculate that genes affected by
the loss of LKB1, but not AMPK, may contribute to
enhanced insulin secretion in the former. Of the
genes most strongly up-regulated in all 3 LKB1KO
models, 4 were unaffected in both AMPKdKOmodels:
Baiap2l2, Cabp1, Rspo4, and Bcl6b (Fig. 5). Bcl6b enc-
odes a transcription factor and downstream target of
FGF2 capable of promoting germ cell tumors (57).
Likewise, RSPO4 is a member of the R-spondin family
of secreted agonists of canonical Wnt/b-catenin sig-
naling that binds to Lgr receptors to enhance cell
growth (58). BAIAP2L2 is a member of the I-BAR do-
main family of proteins involved in the control of actin
dynamics and signaling at glutaminergic synapses (59)
and ﬁlopodia extension (60), and may thus also
be involved in Wnt or Hedgehog signaling. Finally,
CaBP1 is a neuronal calcium binding protein that
regulates several Ca2+ channels, including transient
receptor potential 5 (Trp5; ref. 61).
Regulation of neuronal genes in the b cell by LKB1
and AMPK
A striking ﬁnding of the present study is that both LKB1
and AMPK control the expression of a large number of
neuronal genes in the b cell. LKB1 deletion had the
most dramatic effect on this group of genes (Fig. 4A),
and this effect was also observed after short-term (1 wk)
loss of LKB1 in the Pdx1CreER-deleted model. Several
of the most strongly affected genes, notably Nptx2 and
Dlgap2, were also subject to control by AMPK (Fig. 5).
Thus, both AMPK and AMPKRKs may mediate the
effects of LKB1 on this gene group. Analysis of the
promoter regions of genes regulated by either kinase
revealed several potential downstream regulators
(Table 2), of which Zfp206, a neuron-enriched tran-
scription factor, is an attractive candidate for mediat-
ing these effects.
We also considered the possibility that some of
the changes may be the result of altered expression of
repressor element 1 silencing transcription factor
(REST), which represses neuronal genes in non-
neuronal cells and is also relatively weakly expressed in
unmodiﬁed adult b cells (62). However, while REST
expression was reduced in islets from Ins1LKB1KO
islets, its expression was slightly increased, or barely
affected, in RIP2LKB1KO and Pdx1CreERLKB1KO
islets, respectively, while REST expression was slightly
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increased in both AMPKdKO model islets (Fig. 5).
Nonetheless, differences in REST expression between
Ins1LKB1 and the AMPKdKOs may contribute to the
differential enrichment for neuronal genes (Fig. 4).
Thus, several well-deﬁned targets for REST, including
Snap25 (P50.05) and the synaptotagmin family mem-
ber Syt4 (P,0.01), were up-regulated in Ins1LKB1KO
islets.
Regulation in the b cell of genes involved in glutamate
signaling and addictive behavior
Gria3, encoding the GluR3 glutamate receptor, was
up-regulated in all 5 KO models, while Gria1 (GluR1)
expression was also increased in Ins1LKB1KO islets,
as were Dlgap2 and Nptx2. Nptx2 encodes neuronal
pentraxin 2 (also known as Narp in the rat), which
binds to the extracellular domain of a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic (AMPA)-activated
subclass of glutamate receptors, causing their clustering.
Thus, pentraxins are secreted from presynaptic neurons
(63), and recruit GluR4 AMPA receptors to synapses.
Pentraxins are also implicated in neuronal plasticity and
the behavioral responses to drug abuse (64).
We show that inductionofNptx2 (alongside that of other
genes involved in glutamate signaling; see above) was ac-
companied functionally by enhancedkainite-inducedCa2+
signals, and insulin secretion (Fig. 6B,C).This suggests that
LKB1, and possibly AMPK, are necessary to suppress
pathways that may lead to the dysregulation of secretion
in b cells.
Regulation of disallowed genes by AMPK
Ourﬁndinghere that loss ofAMPK(butnotLKB1) fromb
cells up-regulates the b-cell-disallowed gene family (10)
raises the interesting possibility that this enzyme is a key
determinant in maintaining normal glucose respon-
siveness. Thus, elevated AMPK activity in the b cell be-
tween meals is likely to be required to maintain low levels
of these enzymes. Indeed, AMPK activators such as met-
formin, used clinically as oral antihyperglycemics, may act
in part in this way (18).
We have considered the possibility that an increase
in postprandial glycemia in the AMPKdKO mouse vs.
controls may contribute to the up-regulation of these
genes (6, 65). However, and against this view, neither
fasting (Fig. 1D) nor fed (10.960.26 and 10.86
0.2 mM, for WT and Ins1AMPKdKO mice, respectively;
n54, P.0.05) glycemia differed between genotypes;
and mRNA changes in Ins1AMPKdKO islets were
preserved after culture at 11 mM glucose for 24 h
postisolation.
CONCLUSIONS
LKB1 and AMPK are shown here to be powerful reg-
ulators of b-cell differentiation, acting partly in con-
cert and partly independently of one another.
Although cell fate switching is implied by the effects of
loss-of-function mutations in LKB1 in Peutz-Jeghers
syndrome (19), to our knowledge this report provides
the ﬁrst example of developmental fate being affected
by the fuel-sensitive protein kinase AMPK. Interest-
ingly, these changes occurred without apparent re-
version to a more progenitor-like state, as indicated by
unchanged expression of Ngn3, Oct4, or Nanog, in con-
trast to recently described models (8).
Further dissection of the mechanisms acting down-
stream of LKB1 in b cells may thus provide the basis of
strategies to maintain cellular differentiation in some
forms of diabetes.
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